Get started

Gilead Sciences (Japan)

Homepage: gilead.com
Alternate name: ギリアド・サイエンシズ
ROR: 04getey85
OpenAlex ID: I4405284944
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial
2015 · Masashi Mizokami, Osamu Yokosuka, et al. · The Lancet Infectious Diseases · 362
Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
2018 · Tetsuo Takehara, Naoya Sakamoto, et al. · Journal of Gastroenterology · 118
PDF
Ledipasvir‐sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection
2018 · Yasuhiro Asahina, Yoshito Itoh, et al. · Liver International · 35
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)
2021 · Yoshiya Tanaka, Tsukasa Matsubara, et al. · Modern Rheumatology · 18
PDF
Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors
2024 · Yoichi Naito, Seigo Nakamura, et al. · International Journal of Clinical Oncology · 17
PDF
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
2022 · Toshifumi Hibi, Satoshi Motoya, et al. · Intestinal Research · 16
PDF
Sofosbuvir–velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan
2022 · Tetsuo Takehara, Namiki Izumi, et al. · Hepatology Research · 15
PDF
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2)
2020 · Tsutomu Takeuchi, Tsukasa Matsubara, et al. · Modern Rheumatology · 13
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3)
2022 · Tatsuya Atsumi, Yoshiya Tanaka, et al. · Modern Rheumatology · 11
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort
2025 · Yoshiyuki Yokomaku, Katsuji Teruya, et al. · PLoS ONE · 10
PDF
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results
2022 · Yoshiya Tanaka, Tsukasa Matsubara, et al. · Modern Rheumatology · 10
PDF
Cost–effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan
2024 · Saaya Tsutsué, Shinichi Makita, et al. · Future Oncology · 9
Cost-utility analysis of second-line axicabtagene ciloleucel versus standard of care in Japan based on the ZUMA-7 trial
2024 · Saaya Tsutsué, Shinichi Makita, et al. · Future Oncology · 8
PDF
Relationship between adherence to bictegravir/emtricitabine/tenofovir alafenamide fumarate and clinical outcomes in people with HIV in Japan: a claims database analysis
2024 · Nao Taguchi, Yi Piao, et al. · Scientific Reports · 7
Real‐world safety and effectiveness of tenofovir alafenamide for 144 weeks in Japanese patients with chronic hepatitis B
2024 · Shuhei Hige, Kouji Aoki, et al. · Journal of Viral Hepatitis · 7
PDF
Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study
2023 · Kenji Watanabe, Laurent Peyrin-Biroulet, et al. · Journal of Crohn s and Colitis · 7
PDF
Cost-effectiveness analysis of HIV pre-exposure prophylaxis in Japan
2023 · Daisuke Mizushima, Yoshino Nagai, et al. · Journal of Medical Economics · 7
PDF
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
2022 · Bernard G. Combe, Yoshiya Tanaka, et al. · Rheumatology and Therapy · 7
PDF
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)
2021 · Tatsuya Atsumi, Yoshiya Tanaka, et al. · Modern Rheumatology · 7
PDF
Real‐world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan
2020 · Masashi Mizokami, Lauren J. Liu, et al. · Journal of Viral Hepatitis · 7
Filgotinib Radiographic and Clinical Efficacy Versus Other JAK Inhibitors and Adalimumab in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Systematic Review and Network Meta-Analysis
2025 · Yoshiya Tanaka, Rene Westhovens, et al. · Rheumatology and Therapy · 6
PDF
Real-world treatment persistence in csDMARD-IR and bDMARD-IR patients with rheumatoid arthritis in Japan: A large claims database study
2025 · Tsutomu Takeuchi, Craig Pfeifer, et al. · Modern Rheumatology · 6
Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION Study
2024 · Hiroshi Nakase, Silvio Danese, et al. · Inflammatory Bowel Diseases · 6
PDF
Long-Term Safety, Efficacy, and Patient-Centered Outcomes of Filgotinib in the Treatment of Rheumatoid Arthritis: Current Perspectives
2023 · Yoshiya Tanaka, Mark C Genovese, et al. · Patient Preference and Adherence · 6
PDF
Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
2022 · Yoshiya Tanaka, Tatsuya Atsumi, et al. · Rheumatology and Therapy · 6
PDF
Works count: 80
Citation count: 1,361
Year
Topic
Type